Pfizer Stock Pays Out $50 Bil to Investors in 10 Years
In the last decade, Pfizer (PFE) stock has returned $50 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the market’s biggest capital-return machines.
As it turns out, PFE stock has returned the 54th highest amount to shareholders in history.
| PFE | S&P Median | |
|---|---|---|
| Dividends | $17 Bil | $4.5 Bil |
| Share Repurchase | $33 Bil | $5.5 Bil |
| Total Returned | $50 Bil | $9.1 Bil |
| Total Returned as % of Current Market Cap | 35.4% | 25.7% |
Why should you care? Because dividends and share repurchases represent direct, tangible returns of capital to shareholders. They also signal management’s confidence in the company’s financial health and ability to generate sustainable cash flows. And there are more stocks like that. Here is a list of the top 10 companies ranked by total capital returned to shareholders via dividends and stock repurchases.
That is one way to look at stocks. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure.
Top 10 Stocks By Total Shareholder Return
| Total Money Returned | As % Of Current Market Cap | via Dividends | via Share Repurchases | |
|---|---|---|---|---|
| AAPL | $847 Bil | 23.0% | $141 Bil | $706 Bil |
| MSFT | $364 Bil | 9.5% | $165 Bil | $199 Bil |
| GOOGL | $343 Bil | 11.6% | $12 Bil | $331 Bil |
| XOM | $212 Bil | 43.6% | $145 Bil | $67 Bil |
| WFC | $208 Bil | 81.6% | $59 Bil | $150 Bil |
| JPM | $174 Bil | 20.3% | $0.0 | $174 Bil |
| META | $167 Bil | 9.2% | $6.4 Bil | $160 Bil |
| ORCL | $161 Bil | 18.4% | $34 Bil | $126 Bil |
| JNJ | $157 Bil | 34.1% | $104 Bil | $52 Bil |
| CVX | $153 Bil | 58.4% | $97 Bil | $55 Bil |
For full ranking, visit Buybacks & Dividends Ranking
What do you notice here? The total capital returned to shareholders as a % of the current market cap appears inversely proportional to growth prospects for reinvestments. Stocks like Meta (META) and Microsoft (MSFT) are growing much faster, in a more predictable way, compared to the others, but they have returned a much lower fraction of their market cap to shareholders.
That’s the flip side to high capital returns. Sure, they are attractive, but you have to ask yourself the question: Am I sacrificing growth and sound fundamentals? With that in mind, let’s look at some numbers for PFE. (see Buy or Sell Pfizer Stock for more details)
Pfizer Fundamentals
- Revenue Growth: 13.5% LTM and -12.4% last 3-year average.
- Cash Generation: Nearly 19.5% free cash flow margin and 26.1% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for PFE was -29.1%.
- Valuation: Pfizer stock trades at a P/E multiple of 13.1
- Opportunity vs S&P: Compared to S&P, you get lower valuation, higher LTM revenue growth, and better margins
| PFE | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Pharmaceuticals | – |
| PE Ratio | 13.1 | 23.6 |
|
|
||
| LTM* Revenue Growth | 13.5% | 5.2% |
| 3Y Average Annual Revenue Growth | -12.4% | 5.3% |
| Min Annual Revenue Growth Last 3Y | -29.1% | -0.1% |
|
|
||
| LTM* Operating Margin | 26.1% | 18.6% |
| 3Y Average Operating Margin | 20.2% | 17.8% |
| LTM* Free Cash Flow Margin | 19.5% | 13.3% |
*LTM: Last Twelve Months
That’s a good overview, but evaluating a stock from an investment perspective involves much more. That is exactly what Trefis High Quality Portfolio does. It is designed to reduce stock-specific risk while giving upside exposure.
PFE Historical Risk
Pfizer isn’t immune to big selloffs either. It fell nearly 40% in the Dot-Com crash and over 53% during the Global Financial Crisis. The 2018 correction and Covid dip were smaller but still a solid 24% and 29%, respectively. The recent inflation shock hit it hardest, with a drop of about 54%. So while Pfizer looks stable on paper, history shows it can still take big hits when markets turn sour.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.